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The development of a large animal model of fulmi-
nant hepatic failure produced with acetaminophen 
that should be useful in the development and eval-
uation of potential medical therapies for the impor-
tant clinical problem of fulminant hepatic failure is 
described. Acetaminophen in dimethyl sulfoxide 
(600 mg/ml) given as three subcutaneous injections, 
with the first dose (750 mg/kg body wt) being given 
at noon, the second dose (200 mg/kg body wt) being 
given 9 h later, and the third dose (200 mg/kg body 
wt) being given 24 h after the initial dose consis-
tently produces fulminant hepatic failure in dogs. 
The dimethyl sulfoxide vehicle, injected intramus-
cularly, does not influence either animal survival or 
hepatic function in control-treated dogs. No deaths 
occur within the first 36 h. By 72 h after initial drug 
administration, the mortality is 90%. Histopatholog-
ical and biochemical investigations demonstrate a 
high degree of hepatocellular necrosis in nonsurviv-
ing animals without appreciable damage to the 
kidneys, lungs, or heart. The drug schedule and 
preparation outlined avoids the administration of 
large volumes of vehicle and results in prolonged 
high levels of acetaminophen in the blood sufficient 
to induce severe hepatic injury. Ranitidine (120 mg/ 
kg body wt i.m.l given 30 min before each acetamin-
ophen dose significantly reduces the mortality and 
hepatic necrosis produced using this model. This 
model satisfies all criteria established by Miller et 
al. for the production of a suitable large animal 
model of fulminant acute hepatic failure. 
Amajor deterrent to the development of new therapies for the important clinical problem of 
fulminant hepatic failure is the lack of a safe, reli-
able, and inexpensive large animal model to use in 
such studies (1-3). Currently, the two most fre-
quently used large animal models of fulminant he-
patic failure are produced either as a result of ische-
mic hepatic mJury or acetaminophen-induced 
hepatotoxicity. Ischemic hepatic necrosis necessi-
tates surgical intervention, requires considerable 
technical expertise, involves great expense, and is 
associated with a high degree of model-to-model 
variability (4-10). The second model capitalizes on 
the well-known hepatotoxicity of acetaminophen 
(11-15) and has been studied widely. Unfortunately, 
it has never been standardized or been shown to be 
reproducible, producing inconsistent toxicity from 
animal to animal and between experiments (16-18). 
Potentially, there are three important reasons for 
this lack of reproducible results with the acetamino-
phen model. First, no attention has been given to the 
determination of acetaminophen blood levels in the 
animals being studied despite the fact that it is 
known that high blood levels of the drug are required 
to produce hepatic necrosis. Second, the duration of 
elevated levels of the drug necessary to produce 
consistent panlobular necrosis has not been deter-
mined. Third, no current model of drug-induced 
hepatic necrosis exists using 10-ml volumes of acet-
aminophen solution, which can be easily injected 
subcutaneously. The model reported considers each 
of these three issues. 
Materials and Methods 
Chemicals 
Acetaminophen and dimethyl sulfoxide (DMSO) 
were purchased from Sigma Chemical Co., St. Louis, Mo. 
Pentothal was purchased from Abbott Laboratories, North 
Chicago, Ill. Ranitidine was obtained from Glaxo, Inc., 
Research Triangle Park, N.C. Xylocaine was purchased 
from Astra Pharmaceutical Product, Inc., Worchester, 
Abbreviation used in this paper: DMSO, dimethyl sulfoxide. 
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Mass. Formaldehyde was obtained from Fisher Scientific, 
Pittsburgh, Pa. 
Animals 
One hundred twenty-seven male beagle-mix dogs 
were purchased from Russel B. Hutton Farms, St. Thomas, 
Pa. The dogs were housed in a large animal care facility 
and maintained at a constant temperature of 20° ± 1 DC 
with a 6 AM to 6 PM light cycle. All dogs were quarantined 
and allowed to acclimatize in the animal facility for a 
minimum of 1 wk before being used. All dogs were given 
a standard dry dog food and water ad libitum. Their body 
weights ranged from 9 to 14 kg. 
Study Design 
The animals were randomly divided into four 
groups. 
Group 1 (n = 31) (intravenous administmtion of 
acetaminophen with and without sodium pentothal in-
duction). Thirty-one dogs received an intravenous infu-
sion of 1% acetaminophen in physiologic saline over a 
period of 45 min. In 7 dogs (la), a dose of 700 mg/kg body 
wt was infused. In the remaining 24 dogs (lb), a dose of 
400 mg/kg body wt was infused. Sodium pentothal (25 
mg/kg body wt i.m.) as an inducer of microsomal enzymes 
was administered daily to the animals in group Ib for 4 
days before and on the day of acetaminophen administra-
tion. 
Group 2 (n = 24) (intramuscular administration of 
acetaminophen dissolved in dimethyl sulfoxide). Twen'-
ty-oue dogs were given an intramuscular injection of 
acetaminophen (900 mg/kg body wt dissolved in DMSO at 
a concentration of 600 mg/ml). All of the dogs received 
sodium pentothal (25 mg/kg body wt i.v.) as an anesthetic 
on the day of acetaminophen administration. Three dogs 
were used as controls for this group and were treated with 
the same volume of DMSO given the treated animals but 
without any acetaminophen. 
Group 3 (n = 20) (subcutaneous administration of 
acetaminophen dissolved in dimethyl sulfoxide). Twenty 
dogs were treated with a subcutaneous injection of acet-
aminophen at a dose of 1600 rng/kg body wt, which was 
administered as a solution of acetaminophen in DMSO 
(600 mg/mll. Novocaine was used as a local anesthetic, 
being injected in the areas surrounding the acetaminophen 
injections. 
Group 4 (n = 52) (multiple subcutaneous injections 
of acetaminophen). Fifty-two dogs received a total of 
three time-spaced subcutaneous injections of acetamino-
phen in DMSO at a concentration of 600 mg/ml. The first 
injection of acetaminophen (750 mg/kg body wt) was given 
at noon; the second injection (200 mg/kg body wt) was 
given 9 h later; the third dose (200 mg/kg body wt) was 
given 24 h after the initial dose. This treatment protocol 
was chosen to produce a concentration of drug in serum of 
~14M /Lg/ml for a period of at least 20 h. Previous studies 
have shown that it is important to attain and maintain this 
level for a period of 24 h to produce consistent hepatic 
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necrosis (19). Further, this dosing schedule was selected 
because it is not complicated by the production of methe-
moglobinemia. Twelve of the 52 dogs in this group were 
also given ranitidine (120 mg/kg body wt Lm.) 30-60 min 
before each dose of acetaminophen. 
Biochemical Determinations 
Blood levels of acetaminophen. Five animals in 
each group were used to determine blood acetaminophen 
levels (20). A blood sample of 7 ml was taken from each 
animal at 0, 24,48,60, and 72 h after initial administration 
of acetaminophen. 
Biochemical parameters. Ten dogs in groups 1, 2, 
and 3, and all of the dogs in group 4, had serum glutamic-
pyruvic transaminase, ammonia, urea nitrogen, albumin, 
bilirubin. and cholesterol levels determined before and at 
various times after acetaminophen administration. Stan-
dard laboratory methodology was used for each measure. 
A coagulation profile comprising nine parameters (fi-
brinogen, factors II, V, VII, VIII, IX, X, XI, and XII) was 
obtained at each such assessment. Fibrinogen levels were 
expressed as milligrams per deciliter and the various 
factors as units per milliliter (21-24). Plasma amino acid 
profiles were determined using deproteinized plasma ob-
tained with 4% sulfosalicylic acid treatment of the plasma. 
The resultant supernatant was applied to an amino acid 
analyzer (Beckman Instruments, Somerset, N.J.) and the 
levels of free branched chain and aromatic amino acids 
(including tryptophan) in the plasma were determined. 
Hematology. In addition to all of the above mea-
sures, the hematocrit and the presence of hemoglobinuria 
and methemoglobinemia were assessed in all of the dogs 
in group 4. The methemoglobinemia was quantified in a 
hematology laboratory using a standard methodology (25). 
Histology 
All nonsurviving dogs underwent necropsies that 
included a full histologic evaluation of the liver, kidneys, 
lungs, and heart. Tissues were fixed in 10% neutral buff-
ered formalin, sectioned at 6 /Lm, and stained with hema-
toxylin and eosin. 
The assessment of the degree of hepatic necrosis was 
initially performed using a semiquantitative scale. The 
scale was based on two observations and performed by a 
single staff pathologist who was blinded as to the treat-
ment group: (I) the extent of necrosis within individual 
lobules [(a) mild = less than one-third of the lobule, (b) 
moderate = one-third to two-thirds of the lobule, and (c) 
greater than two-thirds of the lobule]. This initial assess-
ment was then combined within (II) an estimation of the 
number of lobules affected [(a) less than one-third, (b) 
one-thire! to two-thirds. and (c) greater than two-thirds of 
the lobules examined being affected]. 
Statistical Analvsis 
Statistical analyses were performed using a one-
way analysis of variance program in the spec/pc statisti-
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Figure 1. Survival rate and serum glutamic-pyruvic transaminase levels plotted across time in groups 1-4. Each panel shows the 
survival rate in groups Ib, 2-4 (solid line) and in group la (long dash line) expressed as a percentage, and the serum 
glutamic-pyruvic transaminase (alanine aminotransaminase) levels (short dash line) expressed as units per liter. 
cal software (SPSS, Inc., Chicago, Ill.) package on an 
IBM-AT microcomputer. 
Results 
Animal Survival 
The survival data for the animals in groups 1-
4 are summarized in Figure 1. All of the animals in 
group la survived, whereas 80% of the dogs in group 
lb died within 48 h of drug administration. The 
transaminase levels in the group lb dogs increased 
only moderately «180 u/L) (Figure 1), suggesting 
that the mortality experienced in this group may not 
have been due to drug-induced liver injury per se, a 
conclusion that was confirmed by the histopatholog-
ical data. 
All of the dogs in group 2 died within 48 h of drug 
administration, with most of the mortality occurring 
in the first 24 h. Only modestly increased transami-
nase levels were found in these animals. In contrast 
to the treated animals, no change in transaminase 
levels or alteration of liver and kidney histology 
occurred in the 3 DMSO-treated control animals. 
Moreover, none of the controls died. 
The mortality rate was 25% within 24 h, 60% at 48 
h, and 80% at 72 h for group 3. The transaminase 
levels in this group increased markedly up to 600 U/ 
L, suggesting substantial hepatocellular injury in 
these animals. 
No deaths occurred in the first 24 h in group 4. 
Moreover, only a 10% mortality was seen in the next 
24 h. From 48 through 72 h, a progressive increase in 
mortality was observed and achieved a level of 90% 
at 72 h. This group of animals demonstrated a very 
impressive increase in their serum transaminase 
levels. Peak serum glutamic-pyruvic transaminase 
levels (20-25 x 103 u/L) occurred between 48 and 60 
h after initial dosing. It is of interest to note that the 
peak in the transaminase levels often paralleled the 
mortality. 
The effect of ranitidine treatment on the survival 
rate of group 4 dogs is shown in Figure 2. Ranitidine 
had a significant protective effect. At 72 h, the 
survival rate of animals treated with a combination 
of ranitidine and acetaminophen was 80% as com-
pared to only 10% in those given acetaminophen 
alone. 
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Figure 2. Survival rate in group 4 dogs with and without raniti-
dine treatment. The treated animals received a dose of 
120 mg/kg body wt Lm. 30-60 min before each aceta-
minophen iniection. 
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Histopathological Results 
Histologic examinations of the livers obtained 
at the time of autopsy or at death revealed striking 
differences between groups. The liver tissue ob-
tained from dogs in groups 1, 2, and 3 demonstrated 
only occasional areas of centrilobular necrosis in-
volving less than one-fifth of the lobules and less 
than one-fifth of the radius of the hepatic lobule, 
with the central vein being considered as being in 
the center of each lobule. Prominent centrilobular 
sinusoidal congestion was seen also. A mild micro-
vesicular vacuolization of hepatocytes was present 
in several of the animals. In contrast. the liver tissue 
obtained from animals in group 4 demonstrated a 
severe zonal (centrilobular) necrosis, involving all of 
the lobules, with reticulin collapse and occasional 
central-central bridging necrosis (see Figures 3A and 
3B). The degree of necrosis within individual lob-
ules varied from involvement of one-third of the 
lobule in the least severely affected ones to almost 
total involvement in the more affected lobules. The 
hepatocellular necrosis seen in these animals was 
associated with prominent centrilobular congestion, 
hemorrhage, and a mild influx of neutrophils. The 
necrotic cells in the livers of the group 4 animals 
demonstrated cytoaggregation and eosinophilia as 
well as nuclear pyknosis, karyorrhexsis, and kar-
yolysis. The few remaining viable periportal hepa-
tocytes in these animals demonstrated cellular 
swelling and microvacuolization. No histologic ab-
normalities were found in the kidneys, lungs, or 
hearts of these animals. 
Biochemical Results 
Plasma acetaminophen levels. Blood acet-
aminophen levels in the dogs from groups 1-4 are 
depicted in Figure 4. In the animals injected intrave-
nously, intramuscularly, or subcutaneously (groups 
1, 2, and 3) with only a single dose of acetamino-
phen, a rapid increase in acetaminophen levels was 
seen for the first 2-3 h. This was followed by a rapid 
decline in acetaminophen levels over the next 12-15 
h. In the animals in group 4 that received repeated 
subcutaneous injections of acetaminophen, the 
blood level increased for 12 h, at which point they 
began to slowly decline over the next 12 h such that 
an acetaminophen level >140 J-tg/ml was maintained 
for a period of 4-20 h. 
Biochemical parameters. The biochemical 
parameters monitored in the animals from groups 1. 
2, and 3 (data not shown) were inconsistent with a 
significant degree of hepatic necrosis. Table 1 lists 
the various biochemical determinations obtained in 
the animals in group 4. Nonsurviving animals dem-
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onstrated a significant increase in transaminase lev-
els and a significant decrease in cholesterol, albu-
min, and urea nitrogen levels, all of which occurred 
within 48 h of acetaminophen administration. 
Plasma ammonia levels increased rapidly. The max-
imum transaminase level in nonsurviving animals 
was 21,253 ± 3746 U/ml. The maximum transami-
nase level achieved in surviving animals was 1398 ± 
503 UlmI. Moreover, the levels of cholesterol, albu-
min, urea, and ammonia reached to almost the same 
levels in surviving animals as that achieved in the 
nonsurviving animals (Table 1), but recovery to the 
normal level was observed during the last 48 h. 
Table 1 also lists the data for the plasma branched 
chain amino acids, aromatic amino acids, and ratio 
determinations of the two obtained in the animals in 
group 4. An increase in the plasma aromatic amino 
acids was observed in all group 4 animals and, as 
expected, a more pronounced increase was observed 
in the nonsurviving dogs. Bilirubin levels increased 
slowly in both cases without reaching a significant 
statistical value. Table 2 reports the results of the 
various coagulation tests obtained in the surviving 
and nonsurviving animals in group 4. A profound 
depression of all factors measured was observed 
with time in the non surviving animals, which is 
more pronounced than in surviving animals. 
Hematology. A slight reduction in the hema-
tocrit level was found in ~RM°frF of the dogs in group 
4. In 40% of the dogs in group 4, it decreased to 
levels as low as 35% as a result of intestinal hemor-
rhage occurring as part of the syndrome of fulminant 
hepatic failure. Hemoglobinuria and methemoglo-
binemia were not present in any of the dogs (data not 
shown). Similar findings have been reported previ-
ously in dogs subjected to acetaminophen-induced 
hepatic injury (18). 
Clinical Features 
All of the animals in group 4 demonstrated a 
clinical picture consistent with fulminant hepatic 
failure that paralleled the biochemical and histologic 
data. Two different stages of the clinical course of 
these animals could be identified. The first stage was 
characterized by gastrointestinal signs and symp-
toms such as anorexia, vomiting, and diarrhea. The 
second stage was characterized by the appearance of 
neurologic symptQms that rapidly progressed to 
COlua. 
Discussion 
Fulminant hepatic failure in humans carries a 
very high mortality rate and usually represents the 
end stage of one of several different types of hepatic 
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Figure 3. A. Hi stopathological appearance of the liver of group 4 anim als. Note se vere centrilobular necrosis and hemorrhage (CV = 
central ve in) with preservation of some of the periporta l hepato cytes (portal trac t at bottom center) (H&E. x 200). B. The damage 
has resulted in central-central bridging n ecros is (top center to bottom center) with preservati on of periporta l areas (left center 
and bottom ri ght) (H&E. x 2(0). 
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multicenter studies to evaluate potential therapeutic 
modalities that might be applied to this clinical 
problem using a standard protocol. The three studies 
that have been attempted in such cases in humans 
have yielded conflicting results (26-28) . 
4 12 20 28 36 40 4 12 20 28 36 40 
A large animal model of fulminant hepatic failure 
suitable for the development and evaluation of po-
tential therapeutic modalities for this condition has 
yet to be described. During the last 10 yr, acetamin-
ophen toxicity (16-18) and surgically produced 
ischemic necrosis (4-10) have been the most widely 
utilized models of acute hepatic failure. Galactosa-
mine intoxication, a model developed principally in 
rats (29-32)' has not been studied extensively in 
large animals because of the considerable expense of 
the drug. A rabbit model of fulminant hepatic failure 
has been reported by Blitzer et al. (33) but has not 
been widely accepted principally because the rabbit 
is a very difficult animal with which to work. The 
surgical models in current use require considerable 
technical expertise and expensive operating room 
resources. Moreover, because of the expense and 
constraints on operating room time, it is difficult to 
acquire enough animals to obtain results that can be 
handled statistically. Worse yet, the results with 
such models are often inconsistent and are not 
reproducible from animal to animal. 
24 48 24 48 
Hours 
Figure 4. Blood acetaminophen levels in the animals in groups 
1-4. Each panel shows the acetaminophen blood level 
expressed as micrograms per milliliter. 
lllJury: viral infection, drug or chemical injury, or 
vascular insult. The onset and clinical course of 
fulminant hepatic failure is unpredictable, thus it 
has been difficult, if not impossible, to organize 
Acetaminophen is an inexpensive and readily 
available drug. It has been used previously as a 
hepatotoxic agent for the production of acute hepatic 
failure in both large and small animals but with quite 
Table 1. Biochemical Features of Group 4 Dogs 
Oh 24 h 48 h 60 h 72h 96 h 120 h 
Nonsurviving 
sePT (UlL) 41 ± 4 75 ± 5 8206 ± 3000,,·0 21.253 ± 3746,,·b 
Bilirubin (mg/lOO mI) 1.1 ± 0.2 0.9 ± 0.5 1.2 ± D.4 2.0 ± 0.8 
Cholesterol (mg/l00 mI) 108 ±14 91 ± 9 66 ± 22" 54 ± 18" 
Albumin (gllOO mI) 3 ± 0.2 2 ± 0.4 1.9 ± 0.4" 1.8 ± 0.3" 
Ammonia (fLmollL) 82 ± 23 304 ± 1610 525 ± 133o .b 
Urea nitrogen (mg/lOO mI) 26.6 ± 2.8 12 ± 2.1" 6.4 ± 1.9,,·b 
AAA (fLmolllOO mI) 16 ± 2 69.4 ± 3.1 ".b 
BCAA (fLmoI/100 mI) 50.8 ± 3.5 61.4 ± 2.7" 
BCAA/AAA 3.14 ± 0.2:3 0.88 ± 0.08" 
Surviving 
SGPT (UIL) 51 ± 16 71 ± 16 642 ± 163" 932 ± 432" 1398 ± 603" 907±717" 
Bilirubin (mg/lOO mI) 0.8 ± 0.2 0.9 ± D.7 1.3 ± D.5 1.2 ± 0.5 2.0 ± 1.0° 1.B ± 0.7" 1.3 ± 0.8 
Cholesterol (mg/lOO mI) 90 ± 1 83 ± 7 72 ± 20 92 ± 28 85 ± 4:3 B9 ± 10 95 ± 3 
Albumin (g/100 mI) 3 ± 0.2 1.63 ± 0.1" 1.41 ± 0.3" 1.63 ± 0.6 0 1.64 ± 0.1" 1.8 ± 0.2" 2.2 ± 0.10 
Ammonia (fLmollL) 89 ± 14 148 ± 21" 207 ± 19" 284 ± 350 270 ± 12" 241 ± 15" 
Urea nitrogen (mg/lOO ml) 25.1 ± 7 12.2 ± 1.5" 10.1 ± 1.50 5.89 ± 3.6" 7.81 ± 2.3" 14.11 ± 3.5" 20.9 ± 8.5 
AAA (fLmoll100 ml) 18.3 ± 1.2 45 ± 1" 2D ± 3 
BCAA lJ.,tmolll00 ml) 46.3 ± 1.7 64.7 ± 0.7" 50 ± 1 
BCAA/AAA 2.55 ± 0.21 0.99 ± 0.09" 2.5 ± 0.12 
AAA, aromatic amino acids; BCAA. branched chain amino acids; SGPT, serum glutamic-pyruvic transaminase. The values are expressed 
as mean ± SD. up < 0.05 when the values are compared with the basal levels. h]J < 0.05 when the valups of l10nsurviving dogs are 
compared with the values of tho survi\'ing dogs. 
476 FRANCA VILLA ET AL. GASTROENTEROLOGY Vol. 96, No.2, Part 1 
Table 2. Coagulation Profile in Dogs of Group 4 (Surviving and Nonsurviving at Different Times After Intoxication) 
oh 24 h 48 h GO h 72 h 9bh 
Nonsurviving 
Fibrinogen (mg/100 ml) 284 ± 65 169 ± 70" 50 ± 38" 23 ± 32"'/' 
II (U/ml) 1.6 ± 1 0.6 ± 0.4 0.42±0.1" 0.25 ± O.Ol,,·b 
V (Uiml] 6.2 ± 2.7 1.8 ± 0.4" 0.52 ± 0.5" 1.01 ± 0.90 
VII (U/ml) 4.58 ± 2 0.81 ± 0,5" MKO~1 ± 0.06" 0.20 ± 0.04" 
VIII (Ulml] 4.15 ± 0.75 4.18 ± 1.2 2 ± 0.2 0 '/) 2.74 ± 0.6,,·b 
IX (U/ml] 1.79 ± D.76 1.02 ± 0.41 0.55 ± D.l o .b 0.41 ± D.13,,·b 
X [LI/ml) 3.09 ± 1.2 0.84 ± 0.680 D.26 ± 0.08" 0.20 ± 0.02" 
Xl llinnl] 3.2 ± D.44 1.99 ± 0.12" 1.58 ± 0.04" 1.50 ± 0.15" 
XI! (UtmI) 1.1 ± 0.18 D.75 ± 0.2" 0.61 ± 1.5 0.G2 ± D.U" 
Surviving 
Fibrinogen (mg/100 mI) 266 ± 74 253 + 45 100 ± 6" 198 ± 45 145 ± 77 335 ± 194 
lIlli/mI) 1.3 ± D.5 0.6D ± 0.1" 0.5 ± 0.3 D.S ,ct 0.13" 0.8 ± OIl 1.1 ± (U2 
V [U/ml) 7.25 ± 1 1.60 ± I.U" 2.2 ± 0.7" 1.5 ± 1" 1.1 ± 0.8" 4.9 ± 2.1" 
VIlIUimI) 2.70 ± 1 0.85 ± 0.3" 0.66 ± 0.35" 0.55 ± 0.330 0.4 ± 0.1" 3.5 ± 2.4 
VIII (U/ml) 4.8 ± 0.9 4.9 ± 0.7 5.07 ± 2.2 4.82 ± 1.7 2.4 ± 0.2" 8.6 ± 2.3" 
IX (U/ml) 1.5 ± 0.2 1.2 ± 0.2 1 ± 0.3 0.91 ± 0.37 0.7 ± 0.16" 2.14 ± 0.6 
X [Uillll] 2.2 ± 0.5 0.7 ± 0.12" 0.5 ± 0.29" 0.46 ± 0.36" 0.18 ± 0.02" 2 ± 1.8 
XIIL'/ml) 3.2 ± 0.3 2.1 ± 0.4" 1.8 ± 0.34" 1.82 ± 0.5" 1.38 ± 0.020 2.4 ± 0.4" 
XII [Utm!) 1.9 ± 0.3 0.9 ± 0.04" 0.8 ± 0.2" D.7 ± 0.18" 0.6 ± 0.2" 1.1 ± D.3" 
The values are expressed as mean ± SD. " p < 0.05 when the values are comparnd with the basal levels. b p < 0.05 when the values of 
non surviving dogs are compared with the values of the surviving dogs. 
variable results. Nonetheless, the biochemical con-
sequences and mechanisms of acetaminophen-in-
duced liver injury have been investigated exten-
sively. Liver damage has been shown to be related to 
the biotransformation of the drug into an active 
metabolite that binds to hepatocyte macromolecules, 
leading to cellular injury and death (12-15). Binding 
occurs only after cellular stores of glutathione have 
become depleted by >70% (13,15). The hepatic 
toxicity of acetaminophen can be modified by either 
inducers or inhibitors of drug-metabolizing enzymes 
as well as by procedures that modify the level of 
protective electrophilic sulfhydryl compounds 
within the liver (12-15,34). 
The reported results of various experimental mod-
els (11-18) have been compared with the results 
reported by Prescott et a!. (19) of a series of 30 
patients with paracetamol overdose. In humans, the 
plasma acetaminophen level obtained 12 h after 
ingestion has been shown to be the best predictor of 
hepatic injury due to the drug (19). 
None of the previous studies that have evaluated 
acetaminophen toxicity in large animals (11-19) 
have considered this observation. In the present 
report, a procedure has been developed that main-
tains plasma concentrations of acetaminophen for 
up to 20 h at a high enough concentration to create a 
reproducible form of severe hepatic injury that is not 
complicated by the appearance of methemoglobin-
emia. As such this would appear to be the best large 
animal model of fulminant hepatic failure reported 
to date. 
It was impossible to achieve consistent hepatotox-
icity with only a single administration of acetamino-
phen, whether given intravenously or intragastri-
cally (16). A single dose of acetaminophen when 
given either with or without prior induction of 
microsomal enzymes results in significant animal 
mortality which is not due to hepatic injury but is 
due to factors such as methemoglobinemia and car-
diorespiratory failure (35-38). In contrast, the use of 
a multidose drug administration protocol, with 
DMSO as a solvent to allow a slow steady release of 
the drug from the injection site, produces consistent 
severe hepatocellular injury. Importantly, the DMSO 
used as a vehicle does not influence either animal 
survival or hepatic function when used alone in the 
control animals. Thus, the multiple injection proto-
col appears to be the best and easiest currently 
available method to achieve sufficiently high blood 
levels of acetaminophen required to induce both 
consistent and severe hepatic injury. This is demon-
strated clearly in Figures 1 and 4, in which both the 
survival rates and blood levels of acetaminophen 
achieved in the different groups of animals studied 
are shown. Group 4 animals had a high mortality rate 
beginning at 48 h, which peaked at 72 h. Impor-
tantly, mortality coincided with the peak transami-
nase levels. 
All of the animals in group 1 that were not given 
sodium pentothal survived. In contrast, 80% of the 
animals treated with acetaminophen in combination 
with the inducer died. Neither the biochemical nor 
the histopathological data from these animals were 
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consistent with fulminant hepatic necrosis. Similar 
results were obtained using a single dose of acetami-
nophen dissolved in DMSQ, as was the case for 
groups 2 and 3. In both groups, acetaminophen 
levels increased quickly during the first 4 h after 
drug administration but then rapidly decreased 
reaching nonhepatotoxic levels by 8 h after admin-
istration. As was the case in group 1, all of the 
animals in groups 2 and 3 that died failed to dem-
onstrate any biochemical or pathologic evidence of 
fulminant hepatic failure. It is therefore most likely 
that these animals died as a result of a combination 
of methemoglobinemia, kidney failure, or acute car-
diovascular failure, each of which has been shown to 
occur in earlier studies (32-35). In contrast, the data 
obtained from the animals in group 4 demonstrate 
that multiple injections of acetaminophen maintain 
high blood levels of the drug, which leads to consis-
tent severe hepatic injury. The transaminase levels 
in the group 4 animals rise to levels 10-500 times 
basal values. In addition, levels of cholesterol, albu-
min, and various coagulation factors in blood de-
crease, a finding consistent with severe hepatic in-
jury. Moreover, a sharp increase in ammonia levels 
that mirrored the transaminase levels was observed. 
The pattern of plasma amino acid levels rapidly 
changed to that found in acute hepatic failure. Most 
importantly, the histopathological findings demon-
strated massive hepatic necrosis. An elevation of 
serum bilirubin levels did occur (Table 1), but was 
not statistically significant and was lower than that 
reported by others (18). Nonetheless, the complete 
absence of hemoglobinuria and histologic evidence 
of renal, lung, and heart injury clearly document the 
fact that the animals in group 4 died as a result of 
acute hepatic necrosis. 
An interesting observation shown in Figure 2 is 
that ranitidine was almost completely protective. 
This observation is consistent with reports demon-
strating a protective effect of ranitidine therapy in 
rats subjected to hepatotoxic doses of acetamino-
phen (39). The protective effect of ranitidine is 
reported to occur only at very high dosages of rani-
tidine (39). At such concentrations, ranitidine binds 
to cytochrome P450 and prevents the oxidation of 
acetaminophen to its hepatotoxic metabolite (39-
41). 
The data presented with this model of fulminant 
hepatic failure support the following conclusions: 
(a) the amount of acetaminophen used in these 
experiments does not produce clinically important 
injury in organs other than the liver; (b) the DMSO 
used as a vehicle did not affect the results; (c) 
acetaminophen can be used to induce a reproducible 
form of severe hepatic injury in dogs; and (dl raniti-
dine, presumably by inhibiting the oxidation of 
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acetaminophen, prevents the development of fulmi-
nant hepatic failure despite very high levels of 
acetaminophen in dogs. 
In conclusion, our results describe for the first 
time a model of acute hepatic failure in a large 
animal, which can easily be reproduced in any 
laboratory, and which should be very useful in the 
study of mechanisms and therapeutic approaches to 
the important clinical problem of fulminant hepatic 
failure. This model satisfies all of the criteria out-
lined by Miller et a1. (18) for a suitable animal model 
of acute hepatic failure, i.e., the damage is specific to 
the liver, it is effective in an animal, which allows 
eventual human application, the mortality exhibited 
following the administration of the hepatotoxic drug 
occurs in a defined time range, the hepatic failure is 
highly reproducible, and most importantly, it is safe 
for the investigators involved. 
References 
1. Okuda K. Fulminant hepatic failure: a review. In: Picazo J, ed. 
Glucagon in gastroenterology and hepatology. Pharmacologi-
cal, clinical and therapeutic implications. Boston, Mass.: 
MTP Press, 1982. 
2. Trey CG, Davidson CS. The management of fulminant hepatic 
failure. In: Popper H, Shaffner F, eds. Progress in liver 
disease. Volume 3. New York: Grune & Stratton, 1970:382. 
3. Diseases of the liver and biliary tract. Standardization of 
nomenclature, diagnostic criteria and diagnostic methodol-
ogy. Washington, D.C.: Fogarty International Center. 1977. 
Proceedings No. 22. [DHEW Publications No. (NIH) 77-725]. 
4. DeCrott GH, Reuvers CG, Schalm SW. A reproducible model 
of acute hepatic failure by transient ischemia in thE~ pig. J Surg 
Res 1!l78;42:92-100. 
5. Cllervas MV, Golitsin A, Cienfuegos jA. et al. Hepatectomia 
del 70% y anastomosis portocava tennino-Iateral como mo-
delo experimental de insuficiencia hepatica fulminante. Rev 
Esp Ap Enf Digest 1983;64:389-94. 
6. Rappaport Aryl. McDonald MH, Borowy ZJ. Hepatic coma 
following ischemia of the liver. Surg Gynecol Obstet 1953;97: 
748. 
7. Battersby C. Hickman R, Sauders SJ, et al. Liver function in 
the pig: 1. The effects of 30 minutes normothermic ischemia. 
Br I Surg 1974;fi1:27-32. 
8. Fredlund PE. Ockerman PA, Yang ID. Acidosis and increased 
plasma levels of f3-D glucosidase and f3-D galactosidase after 
hepatic inflow occlusion in the pig. Acta Chir Scand 
1974:140:234. 
9. Nodlinger B, DOllvin D, Javaudin L. nt al. An experimental 
study of survival after two hours of normothermic hepatic 
ischemia. Surg Gynecol Obstet19flO:1 f)O:85!l-64. 
10. Harris KA, Wallace AC, Wall WI. Tolerance of the liver to 
ischemia in the pig. I Surg Res 1982;:U:5:!4-3D. 
11. ysalkI~r RM, Racz WJ, McElligott TF. Acetaminophnn-induced 
h')patotoxicity in mice. Lab Invest 1980;42:181. 
12. Mitchell IR, lollow DJ, Potter WZ. et al. Acetaminophen-
induced hepatic necrosis. I. Role of drug metabolism. I 
Pharmacol Exp Ther 1973;187:185-94. 
13. lollow Dj, Mitchell jR, Potter WZ, et al. Acetaminophen-
induced hepatic necrosis. II. Role of covalent binding in vivo. 
J Pharmacal Exp Ther 1973;187:195-202. 
478 FRANCAVILLA ET AL. 
14. Potter WZ, Davis DC. Mitchell JR, et al. Acetaminophen-
induced hepatic necrosis. III. Cytochrome P450 mediated 
covalent binding in vitro. J Pharmacol Exp Ther 1973:187: 
203-10. 
15. Mitchell JR, Jollow OJ, Potter WZ, et al. Acetaminophen-
induced hepatic necrosis. IV. Protective role of glutathione. J 
Pharmacal Exp Ther 1973:187:211-7. 
16. Ortega L, Landa Garcia JI, Torres Garcia A, et al. Acetamino-
phen-induced fulminant hepatic failure in dogs. Hepatology 
1985;5:673-6. 
17. Gazzard BG, Hughes RD, Mellon PI. et al. A dog model of 
fulminant hepatic failure produced by paracetamol adminis-
tration. Br J Exp PathoI1975;56:408. 
18. Miller OJ, Hickman R, Fratter R, et al. An animal model of 
fulminant hepatic failure: a feasibility study. Gastroenterol-
ogy 1976;71:109-13. 
19. Prescott LF, Roscoe P, Wright N, et al. Plasma-paracetamol 
half-lifp- and hepatic necrosis in patients with paracetamol 
overdosage. Lancet 1971;i:519. 
20. Routh JI. Shane NA, Arredondo EG, et al. Determination of 
N-acetyl-p-aminophenol in plasma. Clin Chern 1968;14:882-
99. 
21. Bontempo FA. Lewis JH. Van Thiel DH. The relation of 
preoperative coagulation findings to diagnosis, blood usage, 
and survival in adult liver transplantation. Transplantation 
1985:39:532-6. 
22. Lewis JH. Coagulation defects. JAMA 1961;178:1014. 
23. Lewis JH. Hemostasis and hemorrhage. Sci Clin 1971;1:1-66. 
24. Lewis JH, Spero JA, Hasiba U. Diagnostic methods: laboratory 
tests. In: Bleeding disorders. Garden City, N.Y.: Medical 
Examination Publishing, 1978:22. 
25. Van Assendelfp OW. Spectrophotometry of hemoglobin de-
rivatives. CC Thomas 1970:128-30. 
26. Volpicelli NA. Hepatotrophic effects of insulin and glucagon 
and their potential role in the treatment of hepatic failure. In: 
Picazo J, ed. Glucagon in gastroenterology. Baltimore: Univer-
sity Park Press, 1978:121-34. 
27. Redeker AG. Yamahiro US. Controlled trial of exchange 
transfusion therapy in fulminant hepatitis. Lancet 1973;i:3-6. 
28. Takahashi Y. Shimizu M. Kosaka M. Nationwide statistics of 
severe hepatitis (fulminant hepatitis). Sashin 19aku 1 ~FT9:P4: 
2285-8. 
29. Makowka L, Falk RE. Rotstein LE, et al. Reversal of experi-
mental acute hepatic failure in the rat. J Surg Res 1980:29: 
479-87. 
30. Makowka L, Falk RE, Rotstein LE, 8t al. Cellular transplanta-
tion in the treatment of experimental hepatic failure. Science 
1980;210:901-18. 
GASTROENTEROLOGY Vol. 96, No.2, Part 1 
31. Makowka L. Studies into the reversal of experimental acute 
hepatic failure in the rat by hepatocyte transplantation. Ph.D. 
thesis. University of Toronto, Toronto, Ontario, Canada, 1982. 
32. Francavilla A, DiLeo A, Polirneno L, et al. The effect of 
hepatic stimulatory substance, isolated from regenerating 
hepatic cytosol, and 50,000 and 30n.OOO subfractions in 
enhancing survival in experimental acute hepatic failure in 
rats treated with a-galactosamig1E~K Hepatology 1986:6:1346-
51. 
33. Blitzer BL, Waggoner JG, Jones AE, et al. A model of fulmi-
nant hepatic failure in the rabbit. Gastroenterology 1978;74: 
664-71. 
34. Chiu S, Bhakthan NMG. Experimental acetaminophen-in-
duced hepatic necrosis: biochemical and electron micro-
scopic study of cysteamine protection. Lab Invest 1978;39: 
193. 
35. Evelyn KA, Malloy HT. Microdetermination of oxyhemoglo-
bin and sulphemoglobin in a single sample of blood. J Bioi 
Chem 1938;126:655. 
:l6. McLean S, Murphy BP, Starmer Gi\. 8t al. Methemoglobin 
formation induced by aromatic arnines and arnidps. J Pharm 
PharmacoI1967;19:146. 
:)7. Levenson DJ, Skorecki KL, Narins RG. Acute renal failure 
associated with hepatobiliary disease. In: Brenner BM. La-
zarus JM, eds. Acute renal failure. Philaddphia: WB Saun-
ders, 1983:467-98. 
38. Cobden I, Record CO, Wark MK, et al. Paracetamol-induc.ed 
acute renal failure in the absence of fulminant liver damage. 
Br Med J 1982:284:21-2. 
39. Leonard TB, Morgan DG, Dent JG. Ranitidine-acetaminophen 
interaction: effects on acetaminophen-induced hepatotoxicity 
in Fischer 344 rats. Hepatology 1985;5:480-7. 
40. Rendie S, Kajfez F, Ruf HH. Characterization of cimetidine, 
ranitidine, and related structures' interaction with cyto-
chrome P-450. Drug Metab Dispos 1983;11:137--42. 
41. Rendie S, Alebic Kolbah T, Kajfez F. et al. Interaction of 
ranitidine with liver microsomes. Xenobiotica 1982;12:9-17. 
l{ec:eived June 23, 1987. Accepted August 29. 1988. 
Address requests for reprints to: Antonio Francavilla, M.D., 
Veterans Administration Hospital. Building (i. Circle Drive, Pitts-
burgh, Pennsylvania 15240. 
This study was supported by awards from the Veterans Admin-
istration and Project grants AM-29961, AM-3000l, and AM-
31577, from the National Institutes of Health, Bethesda, Mary-
land, and by grant 887/12/9144 from the Consiglio Nazionale delle 
Ricerche, Italy. 
